logo

For the Inventor, By the Inventor

Winchester, MA, United States of America

David Jonathan Bennett

This inventor holds 13 USPTO granted patents and 14 published patent applications and 11 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Merck Canada Inc., Msd R&d (China) Co., Ltd.. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Jonathan Bennett. Retrieved from https://idiyas.com/inventor/david-jonathan-bennett-ca16ug1l

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 100.0

 

Average Co-Inventor Count = 12.4

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Doylestown, PA (US) (2015)
  • New Hope, PA (US) (2016)
  • Boston, MA (US) (2017)
  • Winchester, MA (US) (2017 - 2024)

Company Filing History:

goldMedal13 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal5 out of 40 
 
Merck Canada Inc.
 patents
bronzeMedal1 out of 10 
 
Msd R&d (China) Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 12275729 - Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-14),
2. 12065438 - Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors (2024-08-20),
3. 11655216 - Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use (2023-05-23),
4. 10961215 - N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use (2021-03-30),
5. 10894775 - Piperidine derivatives as liver X receptor beta agonists, compositions, and their use (2021-01-19),
6. 10752587 - Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use (2020-08-25),
7. 10138255 - Piperazine derivatives as HIV protease inhibitors (2018-11-27),
8. 9994587 - HIV protease inhibitors (2018-06-12),
9. 9840478 - Piperazine derivatives as HIV protease inhibitors (2017-12-12),
10. 9834526 - HIV protease inhibitors (2017-12-05),
11. 9737545 - HIV protease inhibitors (2017-08-22),
12. 9315475 - HIV protease inhibitors (2016-04-19),
13. 9145391 - Bipyridylaminopyridines as Syk inhibitors (2015-09-29),

Title: Discovering the Innovations of David Jonathan Bennett

Introduction

David Jonathan Bennett, an accomplished inventor based in Winchester, MA, has made significant contributions to the field of biochemistry and pharmaceutical sciences. With a remarkable portfolio of 12 patents, Bennett continues to pave the way for innovative treatments and therapeutic solutions. His work primarily focuses on compounds that target various biochemical pathways, offering potential methods for treating complex diseases.

Latest Patents

Among his latest patents, Bennett has developed "Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors." This invention revolves around compounds that inhibit the IDO enzyme, with implications for the treatment or prevention of IDO-associated diseases or disorders. Additionally, he has patented "Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use." This invention introduces certain substituted aryl and heteroaryl ether compounds that function as Liver X-β receptor agonists, showing promise in treating inflammatory diseases and disorders related to cholesterol and lipid metabolism, including Alzheimer's disease.

Career Highlights

David has had an impressive career, contributing his expertise to well-known companies such as Merck Sharp & Dohme Corporation and Merck Canada Inc. His work in these organizations has underscored his commitment to advancing medicinal chemistry and therapeutic development, enabling him to translate his innovative ideas into practical, life-enhancing solutions.

Collaborations

Throughout his career, Bennett has collaborated with esteemed professionals, including Christopher James Bungard and John A. McCauley. These partnerships have not only enriched his research endeavors but also fostered an environment of creativity and advancement in the scientific community.

Conclusion

David Jonathan Bennett exemplifies the spirit of innovation through his dedicated work and groundbreaking patents. His contributions have the potential to profoundly impact the medical field, offering new avenues for addressing critical health challenges. As he continues to develop novel compounds and treatments, the future of his inventions looks promising and filled with possibilities.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…